Something Different

AI-based drug discovery: Chemical vs. drugs (Part 4)

This newsletter is part of a series — here are the links to Part 1, Part 2, Part 3, (this one is Part 4), and Part 5.  Dear All, We had fun in Feb 2020 discussing whether an antibacterial compound discovered using machine learning was a drug or just a chemical. Building on that conversation, the lab that wrote the

Read More »

WHO 2020 clinical/preclinical pipeline review; Chat with WHO’s Peter Beyer

Dear All, WHO have today updated their 2019 clinical/preclinical pipeline review by releasing their 2020 analyses of both the clinical and pre-clinical antibacterial product pipelines (the new 2020 report, the press release). Their 2020 review of antibacterial products in Phase 1 and beyond covers both traditional (n = 43) and non-traditional products (n = 27)

Read More »

CC4CARB solicitation is out (16 Mar 2020 deadline) / Superb WSJ podcast on antibiotic economics

Dear All, I wrote on 3 Jan 2020 (link) about the NIAID contract intended to establish an innovative Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB). The formal solicitation has now gone live and can be found here. The deadline for applications is 16 Mar 2020. Get to it! In parallel, there is a superb Wall Street Journal podcast dated 13 Jan 2020 about

Read More »

Superb podcasts x 2: “Your cancer will be controlled, but you may die of infection” and “Pharma needs to be (and stay) engaged”

Dear All, Clear analyses by our colleagues in the science-focused media are invaluable ways to educate both ourselves and others: we learn new viewpoints while our non-technical friends and colleagues learn what keeps us up at night. On this note, we have two recently released 30-minute podcasts that are very much worth hearing and sharing. 

Read More »

Which came first: The drug or resistance to the drug?

Dear All, Although it seems entirely reasonable that the “Which came first?” chicken vs. egg riddle can be resolved in favor of the egg, a pair of papers in CID suggest that the answer to the parallel question of “drug vs. resistance to the drug” is changing in a way that is NOT in our favor!

Read More »

$50-100k grants to address socioeconomic outcome disparities due to AMR-related factors

Dear All, I was fascinated to see Mayo Clinic’s Global Bridges Healthcare Alliance release an RFP on 21 Oct entitled “Antimicrobial Stewardship (AMS) Programs to Address Health Inequities arising from Socioeconomic Disparities in USA, Europe, Japan, South Korea, Australia and New Zealand.” The RFP is supported by a grant from Pfizer and seeks to “… solicit programs that have

Read More »

RFP: Climate-Sensitive Infectious Disease Modelling

Dear All, And now for something really different! With the recent GRAM report (20 Jan 2022 newsletter) showing that AMR is linked to more deaths that HIV or malaria (#AMRSOS! Andrew Jack and FT team have some great graphics for this … check them out!), we now have an absolutely fascinating call from Wellcome Trust for

Read More »
Scroll to Top